RT Journal Article
SR Electronic
T1 Androgen receptor polyQ alleles and COVID-19 severity in men: a replication study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.25.22271678
DO 10.1101/2022.03.25.22271678
A1 López-Rodríguez, Rosario
A1 Ruiz-Hornillos, Javier
A1 Cortón, Marta
A1 Almoguera, Berta
A1 Minguez, Pablo
A1 Pérez-Tomás, María Elena
A1 Barreda-Sánchez, María
A1 Mancebo, Esther
A1 Ondo, Lorena
A1 Martinez-Ramas, Andrea
A1 Fernández-Caballero, Lidia
A1 ,
A1 Paz-Artal, Estela
A1 Guillen-Navarro, Encarna
A1 Ayuso, Carmen
YR 2022
UL http://medrxiv.org/content/early/2022/04/02/2022.03.25.22271678.abstract
AB Ample evidence indicates a sex-related difference in severity of COVID-19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyQ polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity. In this study, we analyzed this association in a large cohort of 1136 men classified into three groups according to their degree of COVID-19 severity, finding a similar distribution of polyQ alleles among severity groups. Therefore, our results do not support the role of this polymorphism as a biomarker of COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (COVID-19 Research Call, COV20/00181) co-financed by European Development Regional Fund (FEDER, A way to achieve Europe) and contributions from Estrella de Levante and Colabora Mujer. CIBERer (Centro de Investigacion en Red de Enfermedades Raras) is funded by Instituto de Salud Carlos III.R L-R is sponsored by the IIS-Fundacion Jimenez Diaz-UAM Chair in Genomic Medicine. M.C. and B. A. are supported by the Miguel Servet (CP17/00006) and Juan Rodes (JR17/00020) programs, respectively, of the Instituto de Salud Carlos III, co-financed by the European Regional Development Fund (FEDER). The genotyping service (PCA) was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019 of the PEI+D+I 2013-2016, funded by ISCIII and ERDF.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the research ethics committees of each center (Clinical Research Ethics Committee Hospital Universitario Fundacion Jimenez Diaz, Fundacion Jimenez Diaz Biobank, ref. PIC087-20; Clinical Research Ethics Committee Hospital Universitario Virgen de la Arrixaca, Instituto Murciano de Investigacion Biosanitaria Virgen de la Arrixaca Biobank, ref. COVID-19 RMu; and Clinical Research Ethics Committee Hospital 12 de Octubre). The STOP_Coronavirus cohort received Clinical Research Ethics Committee approval PIC087-20 from Hospital Universitario Fundacion Jimenez Diaz. Wherever possible, patients provided written or verbal informed consent to participate. Due to the health emergency, the research ethics committees of each center waived the requirement for informed consent for the STOP_Coronavirus cohort. All samples were de-identified (pseudonymized) and clinical data were managed in accordance with national legislation and institutional requirements.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors